Last updated: 20 June 2024 at 8:32pm EST

Sciences, Inc. Gilead Net Worth




The estimated Net Worth of Sciences, Inc. Gilead is at least $964 Thousand dollars as of 17 June 2024. Sciences Gilead owns over 179,500 units of AlloVir stock worth over $964,419 and over the last 18 years Sciences sold ALVR stock worth over $0.

Sciences Gilead ALVR stock SEC Form 4 insiders trading

Sciences has made over 5 trades of the AlloVir stock since 2021, according to the Form 4 filled with the SEC. Most recently Sciences bought 179,500 units of ALVR stock worth $136,420 on 17 June 2024.

The largest trade Sciences's ever made was buying 15,238,095 units of AlloVir stock on 29 January 2024 worth over $319,999,995. On average, Sciences trades about 4,168,078 units every 205 days since 2006. As of 17 June 2024 Sciences still owns at least 1,268,972 units of AlloVir stock.

You can see the complete history of Sciences Gilead stock trades at the bottom of the page.



What's Sciences Gilead's mailing address?

Sciences's mailing address filed with the SEC is 333 LAKESIDE DRIVE, , FOSTER CITY, CA, 94404.

Insiders trading at AlloVir

Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red..., and Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.



What does AlloVir do?

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.



Complete history of Sciences Gilead stock trades at Assembly Biosciences Inc, Arcus Biosciences Inc, and AlloVir

Insider
Trans.
Transaction
Total value
Sciences, Inc. Gilead
10% owner
Buy $2,721,220
17 Jun 2024
Sciences, Inc. Gilead
10% owner
Buy $319,999,995
29 Jan 2024
Sciences, Inc. Gilead
10% owner
Buy $19,452,600
28 Jun 2023
Sciences, Inc. Gilead
10% owner
Buy $220,350,000
31 Jan 2021
Sciences, Inc. Gilead
10% owner
Buy $10,990,763
27 Jun 2023


AlloVir executives and stock owners

AlloVir executives and other stock owners filed with the SEC include: